Cullinan Oncology, Inc. (CGEM) Tops Q3 EPS by 43c

Cullinan Oncology, Inc. (NASDAQ: CGEM) reported Q3 EPS of ($0.54), $0.43 better than the analyst estimate of ($0.97). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Cullinan Oncology, Inc. (CGEM) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Ennis (EBF) Reports In-Line Q1 EPS
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance